Follow The Filings

EWTX Edgewise Therapeutics Inc.

Health Care, filed as EDGEWISE THERAPEUTICS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2

  • 2 Owners
  • Max 1.8%
  • $30M
  • 1 add

In 2026 Q2 Nathan Fischel added to Edgewise Therapeutics.

Who owns this now

Largest portfolio weights among holders, up to 1.8% (James Silverman, Opaleye Management). Not free-float ownership.

  1. James Silverman 1.8%
  2. Nathan Fischel Add 1.8%

Who owns EWTX

Sorted by value, long equity only, as of 2026 Q2.

History
James Silverman, Opaleye Management 1.8% Hold 500,000 $20M History
Nathan Fischel, Dafna Capital Management 1.8%, was 0.81% Add +102.1% 226,819 $9.2M History

2 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by EWTX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All EWTX insider trades
  • $199K bought by 1 insider
  • $2.1M sold by 1 insider outside a trading plan
  • $15.6M sold by 3 insiders under 10b5-1 plans
  1. Joanne M. Donovan CMO
    Planned sale
    $127K 2,919 shares at $43.41 25% of stake
    Traded Aug 13 Filed Aug 14
    ↗
  2. Alan J Russell Chief Scientific Officer
    Planned sale
    $7.9M 200,000 shares at $39.41 89% of stake
    Traded Jul 1 Filed Jul 2
    ↗
  3. Joanne M. Donovan CMO
    Planned sale
    $2.1M 55,230 shares at $37.88 93% of stake
    Traded May 4–5 Filed May 5
    ↗
  4. Joanne M. Donovan CMO
    Planned sale
    $926K 28,662 shares at $32.31 75% of stake
    Traded Apr 1 Filed Apr 2
    ↗
  5. Joanne M. Donovan CMO
    Planned sale
    $685K 21,338 shares at $32.12 69% of stake
    Traded Mar 31 Filed Mar 31
    ↗
  6. Joanne M. Donovan CMO
    Planned sale
    $507K 16,358 shares at $30.98 63% of stake
    Traded Mar 27 Filed Mar 30
    ↗
  7. Badreddin Edris Director
    Planned sale
    $3.4M 115,471 shares at $29.44 85% of stake
    Traded Jan 21 Filed Jan 23
    ↗
  8. Alan J Russell Chief Scientific Officer
    Sale
    $2.1M 100,000 shares at $21.12 81% of stake
    Traded Nov 12, 2025 Filed Nov 13, 2025
    ↗
  9. Jonathan C Fox Director
    Buy
    $199K 10,700 shares at $18.64 +82% to stake
    Traded Nov 11, 2025 Filed Nov 13, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 21 option exercises, 18 sales to cover taxes, and 4 stock grants.

SEC filings

Recent issuer filings from EDGAR, 16 shown.

Filed Form Detail Links
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K/A 9.01 Filing Doc
8-K 2.01,7.01,9.01 Filing Doc
8-K 5.07 Filing Doc
8-K 1.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
SCHEDULE 13D/A — Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc

Source: SEC EDGAR submissions, updated 6 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Net income -$100.16M -$133.81M -$167.8M

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $327M $475.48M $543.38M
Total non-current assets * $13.04M $11.33M $9.22M
Total assets $340.04M $486.82M $552.6M
Total current liabilities $16.77M $23.86M $27.37M
Total non-current liabilities * $4.43M $3.74M $2.98M
Total equity $318.83M $459.22M $522.26M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$91.95M -$109.03M -$143.82M
Cash from investing $102.89M -$184.66M -$32.79M
Cash from financing $53.17M $249.25M $196.09M
Net change in cash $64.1M -$44.43M $19.48M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.